 | Up a level |
Journal Article
Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A. M., Busch, R., Mayer, J., Hensel, M., Hopfinger, G., Hess, G., von Gruenhagen, U., Bergmann, M., Catalano, J., Zinzani, P. L., Caligaris-Cappio, F., Seymour, J. F., Berrebi, A., Jaeger, U., Cazin, B., Trneny, M., Westermann, A., Wendtner, C. M., Eichhorst, B. F., Staib, P., Buehler, A., Winkler, D., Zenz, T., Boettcher, S., Ritgen, M., Mendila, M., Kneba, M., Doehner, H. and Stilgenbauer, S. (2010). Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet, 376 (9747). S. 1164 - 1175. NEW YORK: ELSEVIER SCIENCE INC. ISSN 0140-6736
Loeschcke, K., Fink, A., Bahlo, J., Westermann, A., Zey, A., Fischer, K., Wendtner, C. M., Noesslinger, T., Ghia, P., Bosch, F., Kater, A. P., Kreuzer, K. A., Stilgenbauer, S., Boettcher, S., Eichhorst, B. and Hallek, M. (2014). CENTRAL SCREENING ENABLES IDENTIFICATION OF HIGH RISK CLL PATIETNS FOR LENALIDOMIDE MAINTENANCE THERAPY WITHIN THE CLLM1 TRIAL OF THE GERMAN CLL STUDY GROUP. Haematologica, 99. S. 587 - 589. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Westermann, A., Fink, A., Zey, A., Wesselmann, J. S., Busch, R., Fischer, K., Wendtner, C., Kreuzer, K-A, Stilgenbauer, S., Boettcher, S., Eichhorst, B. and Hallek, M. (2014). Screening supported by a central review allows a precise selection of the population for maintenance therapy within the CLLM1 trial of the German CLL Study Group. Oncol. Res. Treat., 37. S. 85 - 86. BASEL: KARGER. ISSN 2296-5262